Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous ovarian cancer immunogene-modified T lymphocytes

A preparation of autologous immunogene modified T lymphocytes (IgT) that have been genetically engineered to be specifically reactive to ovarian cancer (OC) cells, with potential antineoplastic and immunostimulating activities. Upon administration of the autologous OC-IgT cells, the T cells recognize and induce specific toxicity in the OC cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous human OC-IgT cells
OC-IgT cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search